EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Guardant Health's Enterprise Value is $5,129.1 Mil.
Guardant Health's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2022 was $-309.5 Mil. Therefore, Guardant Health's EV-to-FCF for today is -16.57.
The historical rank and industry rank for Guardant Health's EV-to-FCF or its related term are showing as below:
GH'
s EV-to-FCF Range Over the Past 10 Years
Min: -117.99 Med: -64.91 Max: -13.16
Current: -16.57
During the past 6 years, the highest EV-to-FCF of Guardant Health was -13.16. The lowest was -117.99. And the median was -64.91.
GH's EV-to-FCF is ranked worse than 100% of 113
companies
in the Medical Diagnostics & Research industry
Industry Median: 22.20
vs GH: -16.57
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2022-06-27), Guardant Health's stock price is $46.25.
Guardant Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2022 was $-4.120. Therefore, Guardant Health's PE Ratio for today is At Loss.
Competitive Comparison
For the Diagnostics & Research subindustry, Guardant Health's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guardant Health EV-to-FCF Distribution
For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Guardant Health's EV-to-FCF falls into.
Guardant Health EV-to-FCF Calculation
Guardant Health's EV-to-FCF for today is calculated as:
Guardant Health's current Enterprise Value is $5,129.1 Mil.
Guardant Health's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-309.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guardant Health (NAS:GH) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Guardant Health's PE Ratio for today is calculated as:
Guardant Health's share price for today is $46.25.
Guardant Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.120.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Guardant Health EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Guardant Health's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company's pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
1.79(4.03%) Volume: 2,096,243 10:08PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:GH has been successfully added to your 
